Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2020. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
ERYTECH to Present at the LifeSci Partners 10 th Annual Healthcare Corporate Access Event Lyon (France) and Cambridge, MA (U.S.), January 4, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
A total of 510 patients enrolled Events required to trigger interim superiority analysis accrued Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021 LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a
LYON, France and CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announce d today that CEO, Gil Beyen, will
LYON, France, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
W ebcast today, Monday, December 7 at 4:00 pm CET/10:00 am ET The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-asparaginase LYON, France and CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq &
Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET LYON, France and CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
LYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced t o day that its CEO, Gil Beyen, will present an update at the Jefferies Virtual London Healthcare Conference at 12 :00 pm EST / 05:00pm GMT / 6 :00 pm CET on November 18, 2020.
Conference call and webcast on Friday, November 6 at 2:30 pm CET/8:30 am ET TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer: More than 9 5 % of the approximately 500 patients enrolled Number of events required for the interim superiority analysis has been reached Interim
Oral presentation to discuss f indings from the Nordic Society of Paediatric Haematology and Oncology ( NOPHO ) - sponsored Phase 2 trial that confirm the potential of e ryaspase as a treatment option for ALL Second abstract of n ew analysis supporting p opulation p harmacokinetics of e ryaspase in
